How to buy BioCryst Pharmaceuticals stock - 20 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy BioCryst Pharmaceuticals stock

Own BioCryst Pharmaceuticals stock in just a few minutes.

BioCryst Pharmaceuticals, Inc is a biotechnology business based in the US. BioCryst Pharmaceuticals shares (BCRX) are listed on the NASDAQ and all prices are listed in US Dollars. BioCryst Pharmaceuticals employs 246 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in BioCryst Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BCRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

BioCryst Pharmaceuticals share price

Use our graph to track the performance of BCRX stocks over time.

BioCryst Pharmaceuticals shares at a glance

Information last updated 2021-04-15.
52-week range$2.75 - $14.24
50-day moving average $11.24
200-day moving average $7.74
Wall St. target price$14.56
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.15

Buy BioCryst Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy BioCryst Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BioCryst Pharmaceuticals financials

Revenue TTM $17.8 million
Gross profit TTM $-106,828,000
Return on assets TTM -42.83%
Return on equity TTM -1925.37%
Profit margin 0%
Book value $0.19
Market capitalisation $2 billion

TTM: trailing 12 months

Shorting BioCryst Pharmaceuticals shares

There are currently 23.3 million BioCryst Pharmaceuticals shares held short by investors – that's known as BioCryst Pharmaceuticals's "short interest". This figure is 12.5% down from 26.7 million last month.

There are a few different ways that this level of interest in shorting BioCryst Pharmaceuticals shares can be evaluated.

BioCryst Pharmaceuticals's "short interest ratio" (SIR)

BioCryst Pharmaceuticals's "short interest ratio" (SIR) is the quantity of BioCryst Pharmaceuticals shares currently shorted divided by the average quantity of BioCryst Pharmaceuticals shares traded daily (recently around 7.3 million). BioCryst Pharmaceuticals's SIR currently stands at 3.22. In other words for every 100,000 BioCryst Pharmaceuticals shares traded daily on the market, roughly 3220 shares are currently held short.

However BioCryst Pharmaceuticals's short interest can also be evaluated against the total number of BioCryst Pharmaceuticals shares, or, against the total number of tradable BioCryst Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioCryst Pharmaceuticals's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 BioCryst Pharmaceuticals shares in existence, roughly 130 shares are currently held short) or 0.1413% of the tradable shares (for every 100,000 tradable BioCryst Pharmaceuticals shares, roughly 141 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioCryst Pharmaceuticals.

Find out more about how you can short BioCryst Pharmaceuticals stock.

BioCryst Pharmaceuticals share dividends

We're not expecting BioCryst Pharmaceuticals to pay a dividend over the next 12 months.

BioCryst Pharmaceuticals share price volatility

Over the last 12 months, BioCryst Pharmaceuticals's shares have ranged in value from as little as $2.75 up to $14.24. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioCryst Pharmaceuticals's is 2.6531. This would suggest that BioCryst Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

BioCryst Pharmaceuticals overview

BioCryst Pharmaceuticals, Inc. , a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. BioCryst Pharmaceuticals, Inc. has collaborations and in-license relationships with the Torii Pharmaceutical Co. , Ltd.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site